Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07189897 · ClinicalTrials.gov registry record · Phase 4
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
A Phase 4 study of Head and Neck Cancer and Venous Thromboembolism, sponsored by Kiranya Arnold.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT07189897: Recruiting Phase 4 study of Head and Neck Cancer and Venous Thromboembolism, sponsored by Kiranya Arnold.
NCT07189897 is a Phase 4 study of Head and Neck Cancer and Venous Thromboembolism that is actively recruiting participants, run by Kiranya Arnold. The registered enrollment target is 76 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07189897, a Phase 4 study of Head and Neck Cancer and Venous Thromboembolism, is actively recruiting participants, sponsored by Kiranya Arnold.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines. The main questions it aims to answer are: Can apixaban be used safely instead of enoxaparin to prevent blood clots after surgery? Do patients find apixaban easier or more satisfying to take than enoxaparin? How well do patients follow the treatment plan with each medicine? Researchers will compare 2 groups: One group will take apixaban (a pill taken twice a day) for 10 days after surgery. The other group will take enoxaparin (a shot given once a day) for 10 days after surgery. Participants will: Take either apixaban or enoxaparin starting 12-24 hours after surgery, for 10 days total Keep a medication diary and bring back unused medicine so the study team can check adherence Complete short surveys about satisfaction with their medicine Have an ultrasound of their legs to check for blood clots 11-14 days after surgery Return for follow-up visits about 40 days and 80 days after surgery for safety checks How long will participation last? About 4 months from surgery through the last follow-up visit.
Primary Outcome
Enrollment rate will be calculated as the number of participants enrolled, divided by the number of eligible participants, multiplied by 100%.
Conditions Studied
Interventions
- DRUG Apixaban
- DRUG Enoxaparin
Study Locations (1)
New York
- SUNY Upstate - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
What NCT07189897 shows while recruiting
NCT07189897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Apixaban is the first listed.
NCT07189897 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07189897 about?
NCT07189897 is a clinical study titled "Apixaban or Enoxaparin After Head and Neck Cancer Surgery". The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines. The main questions it aims to answer are: Can ap...
What is the current status of trial NCT07189897?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2025-10. Estimated completion is 2027-12.
What conditions does trial NCT07189897 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Venous Thromboembolism.
What interventions are being tested in trial NCT07189897?
The interventions under investigation include: Apixaban (DRUG), Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT07189897?
This trial is sponsored by Kiranya Arnold, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07189897 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07189897's enrollment target sits among peer trials
76 99th of 250 higher than 152 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
COMPLETED · Phase 4
-
3D Specimen Maps for RT Planning
RECRUITING
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia